G. Holt, Mayanka Batra, M. Murthi, S. Kambali, K. Santos, Maria Virginia Perez Bastidas, H. Asif, Sara Haddadi, S. Arias, M. Mirsaeidi
Scientific reports, 2020
Off-label tocilizumab use in COVID-19 patients reflects concern for cytokine release syndrome. Comparison of matched COVID-19 pneumonia patients found elevated IL-6 levels correlated with mortality that did not change with tocilizumab administration. Correlating mortality with increased IL-6 doesn’t imply causality however lack of improvement by tocilizumab requires further clinical trial alterations.
Cited by 9 publications.
Field of study: Medicine